Article
Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI‑1
- Authors:
-
View Affiliations / Copyright
Affiliations:
Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, P.R. China
-
Pages:
295-299
|
Published online on:
October 19, 2012
https://doi.org/10.3892/etm.2012.755
- Expand metrics +
Metrics:
Total
Views: 0
(Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0
(Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
The aim of this study was to investigate whether calcium dobesilate (calcium dihydroxy‑2,5‑benzenesulfonate) may be used to treat diabetic nephropathy. A total of 121 patients with type 2 diabetic nephropathy received calcium dobesilate (500 mg, 3 times a day) for 3 months. The levels of glycated hemoglobin, fasting serum C peptide, triglyceride, total cholesterol, low‑density lipoprotein cholesterol, high‑density lipoprotein cholesterol, alanine aminotransferase, γ-glutamyl transferase, urea nitrogen, creatinine, hematocrit, plasma viscosity, whole blood reduced viscosity, high, medium and low shear rate whole blood viscosity, fibrinogen, plasminogen activator inhibitor‑1 (PAI‑1) and endothelin were determined. The urinary albumin excretion rate (UAER) was also determined once a month during the study. The UAER and medium and low shear rate whole blood viscosity were significantly lower in the treated patients. The rate of microalbuminuria normalization was 90%. During the treatment, the UAERs decreased. The results revealed that calcium dobesilate has therapeutic effects on type 2 diabetes patients with microalbuminuria. In addition, the benefit was positively correlated with the calcium dobesilate treatment time. The therapeutic effect may be due to decreases in the levels of PAI‑1.
View References
|
1
|
Menon R, Mohd Noor FS, Draman CR, Seman MR
and Ghani AS: A retrospective review of diabetic nephropathy
patients during referral to the sub-urban nephrology clinic. Saudi
J Kidney Dis Transpl. 23:1109–1114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernández IS, Cuevas P, Angulo J, et al:
Gentisic acid, a compound associated with plant defense and a
metabolite of aspirin, heads a new class of in vivo fibroblast
growth factor inhibitors. J Biol Chem. 285:11714–11729.
2010.PubMed/NCBI
|
|
3
|
Allain H, Ramelet AA, Polard E and
Bentué-Ferrer D: Safety of calcium dobesilate in chronic venous
disease, diabetic retinopathy and haemorrhoids. Drug Saf.
27:649–660. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ribeiro ML, Seres AI, Carneiro AM, Stur M,
Zourdani A, Caillon P and Cunha-Vaz JG; DX-Retinopathy Study Group:
Effect of calcium dobesilate on progression of early diabetic
retinopathy: a randomised double-blind study. Graefes Arch Clin Exp
Ophthalmol. 244:1591–1600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cuevas P and Arrazola JM: Therapeutic
response of rosacea to dobesilate. Eur J Med Res. 10:454–456.
2005.PubMed/NCBI
|
|
6
|
Cuevas P and Arrazola JM: Dobesilate in
the treatment of plaque psoriasis. Eur J Med Res. 10:373–376.
2005.PubMed/NCBI
|
|
7
|
Reutens AT and Atkins RC: Epidemiology of
diabetic nephropathy. Contrib Nephrol. 170:1–7. 2011. View Article : Google Scholar
|
|
8
|
Liu HX and Han XY: The clinical
observation of the conductivity of the treatment of diabetic
nephropathy. J Hunan Med Univ. 19:423–425. 1994.(In Chinese).
|
|
9
|
Androulakis G and Panoysis PA:
Plethysmographic confirmation of the beneficial effect of calcium
dobesilate in primary varicose veins. Angiology. 40:1–4. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sinzinger H, Rauscha F and Vinazzer H:
Platelet function and prostaglandins in patients with peripheral
vascular disease treated with calcium dobesilate. Prostaglandins
Leukot Med. 29:1–9. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Benarroch IS, Brodsky M, Rubinstein A, et
al: Treatment of blood hyperviscosity with calcium dobesilate in
patients with diabetic retinopathy. Ophthalmic Res. 17:131–138.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun SX, Wang H and Sun XQ: Calcium
dobesilate in the pharmacology and clinical application. J Hos
Pharma. 23:100–101. 2003.(In Chinese).
|
|
13
|
Zhong H and Guo L: The plasma levels of
endothelin in diabetic retinopathy and their changes after
treatment with doxium. Hunan Yi Ke Da Xue Xue Bao. 22:56–58.
1997.(In Chinese).
|
|
14
|
Yang JX: Clinical application of Calcium
dobesilate. Foreign medicine. 25:9–11. 1998.(In Chinese).
|
|
15
|
Tejerina T and Ruiz E: Calcium dobesilate:
pharmacology and future approaches. Gen Pharmacol. 31:357–360.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simpson LO, Shand BI and Olds RJ: A
reappraisal of the influence of blood rheology on glomerular
filtration and its role in the pathogenesis of diabetic
nephropathy. J Diabet Complications. 1:137–144. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simpson LO: Intrinsic stiffening of red
blood cells as the fundamental cause of diabetic nephropathy and
microangiopathy: a new hypothesis. Nephron. 39:344–351. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gordge MP, Patel A, Faint RW, et al: Blood
hyperviscosity and its relationship to progressive renal failure in
patients with diabetic nephropathy. Diabet Med. 7:880–886. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Költringer P, Eber O, Rothlauer W, Klima
G, et al: Calcium dobesilate and its effects on hemorheology and
microcirculation. Int J Clin Pharmacol Ther Toxicol. 26:500–502.
1988.
|
|
20
|
Vojnikovic B: Doxium (calcium dobesilate)
reduces blood hyperviscosity and lowers elevated intraocular
pressure in patients with diabetic retinopathy and glaucoma.
Ophthalmic Res. 23:12–20. 1991. View Article : Google Scholar
|
|
21
|
Yang JK, Yuan SY and Feng LZ: Calcium
dobesilate on the blood rheology and thrombosis formation in rats.
J Chin Microcirculation. 7:20–23. 2003.(In Chinese).
|
